{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:05:28Z","timestamp":1773662728002,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-026-00454-6","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:49:15Z","timestamp":1770695355000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular signaling proteins as predictors of the cardiac effects of doxorubicin treatment in children with acute lymphoblastic leukemia"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2077-6178","authenticated-orcid":false,"given":"Steven E.","family":"Lipshultz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4450-8637","authenticated-orcid":false,"given":"Holly M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1064-8981","authenticated-orcid":false,"given":"Stephen E.","family":"Sallan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7584-0700","authenticated-orcid":false,"given":"Douglas B.","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"issue":"1","key":"454_CR1","first-page":"11","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"454_CR2","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","volume":"109","author":"A Moghrabi","year":"2007","unstructured":"Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, et al. Results of the Dana-Farber cancer Institute ALL consortium protocol 95\u2009\u2013\u200901 for children with acute lymphoblastic leukemia. Blood. 2007;109(3):896\u2013904.","journal-title":"Blood"},{"issue":"8","key":"454_CR3","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1517\/14656566.8.8.1039","volume":"8","author":"E Barry","year":"2007","unstructured":"Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother. 2007;8(8):1039\u201358.","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"454_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1200\/JCO.1996.14.2.328","volume":"14","author":"SE Lipshultz","year":"1996","unstructured":"Lipshultz SE. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. J Clin Oncol. 1996;14(2):328\u201331.","journal-title":"J Clin Oncol"},{"issue":"12","key":"454_CR5","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1200\/JCO.2005.12.121","volume":"23","author":"SE Lipshultz","year":"2005","unstructured":"Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23(12):2629\u201336.","journal-title":"J Clin Oncol"},{"issue":"2","key":"454_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/0192623307313010","volume":"36","author":"J Zhang","year":"2008","unstructured":"Zhang J, Knapton A, Lipshultz SE, Weaver JL, Herman EH. Isoproterenol-induced cardiotoxicity in sprague-dawley rats: correlation of reversible and irreversible myocardial injury with release of cardiac troponin T and roles of iNOS in myocardial injury. Toxicol Pathol. 2008;36(2):277\u20138.","journal-title":"Toxicol Pathol"},{"issue":"8","key":"454_CR7","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1200\/JCO.2009.26.5751","volume":"28","author":"SE Lipshultz","year":"2010","unstructured":"Lipshultz SE, Adams MJ. Cardiotoxicity after childhood cancer: beginning with the end in Mind. J Clin Oncol. 2010;28(8):1276\u201381.","journal-title":"J Clin Oncol"},{"issue":"22","key":"454_CR8","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1200\/JCO.2007.14.9401","volume":"26","author":"L Gianni","year":"2008","unstructured":"Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol. 2008;26(22):3777\u201384.","journal-title":"J Clin Oncol"},{"issue":"3 Suppl 8","key":"454_CR9","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1053\/j.seminoncol.2006.04.019","volume":"33","author":"SE Lipshultz","year":"2006","unstructured":"Lipshultz SE. Exposure to anthracyclines during childhood causes cardiac injury. Semin Oncol. 2006;33(3 Suppl 8):S8\u201314.","journal-title":"Semin Oncol"},{"issue":"10","key":"454_CR10","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/cr.2017.87","volume":"27","author":"M Abdul-Ghani","year":"2017","unstructured":"Abdul-Ghani M, Suen C, Jiang B, Deng Y, Weldrick JJ, Putinski C, et al. Cardiotrophin 1 stimulates beneficial myogenic and vascular remodeling of the heart. Cell Res. 2017;27(10):1195\u2013215.","journal-title":"Cell Res"},{"issue":"19","key":"454_CR11","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1042\/CS20200230","volume":"134","author":"A Geissler","year":"2020","unstructured":"Geissler A, Ryzhov S, Sawyer DB. Neuregulins: protective and reparative growth factors in multiple forms of cardiovascular disease. Clin Sci (Lond). 2020;134(19):2623\u201343.","journal-title":"Clin Sci (Lond)"},{"issue":"46","key":"454_CR12","doi-asserted-by":"publisher","first-page":"13144","DOI":"10.1073\/pnas.1616168113","volume":"113","author":"M R\u00e4s\u00e4nen","year":"2016","unstructured":"R\u00e4s\u00e4nen M, Degerman J, Nissinen TA, Miinalainen I, Kerkel\u00e4 R, Siltanen A, et al. VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection. Pro Natl Acad Sci USA. 2016;113(46):13144\u20139.","journal-title":"Pro Natl Acad Sci USA"},{"issue":"15","key":"454_CR13","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.2174\/138161209788186290","volume":"15","author":"MY Abeywardena","year":"2009","unstructured":"Abeywardena MY, Leifert WR, Warnes KE, Varghese JN, Head RJ. Cardiovascular biology of interleukin-6. Curr Pharm Des. 2009;15(15):1809\u201321.","journal-title":"Curr Pharm Des"},{"key":"454_CR14","doi-asserted-by":"crossref","unstructured":"Kanno SI, Hara A. The mRNA expression of Il6 and Pdcd1 are predictive and protective factors for doxorubicin\u2013induced cardiotoxicity. Mol Med Rep. 2021;23(2):113.","DOI":"10.3892\/mmr.2020.11752"},{"issue":"2","key":"454_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.yjmcc.2008.11.002","volume":"46","author":"P Calabro","year":"2009","unstructured":"Calabro P, Limongelli G, Riegler L, Maddaloni V, Palmieri R, Golia E, et al. Novel insights into the role of cardiotrophin-1 in cardiovascular diseases. J Mol Cell Cardiol. 2009;46(2):142\u20138.","journal-title":"J Mol Cell Cardiol"},{"issue":"4","key":"454_CR16","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1073\/pnas.92.4.1142","volume":"92","author":"D Pennica","year":"1995","unstructured":"Pennica D, King KL, Shaw KJ, Luis E, Rullamas J, Luoh SM, et al. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Pro Natl Acad Sci USA. 1995;92(4):1142\u20136.","journal-title":"Pro Natl Acad Sci USA"},{"issue":"5","key":"454_CR17","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.cyto.2005.01.016","volume":"30","author":"N Lopez","year":"2005","unstructured":"Lopez N, Diez J, Fortuno MA. Characterization of the protective effects of cardiotrophin-1 against non-ischemic death stimuli in adult cardiomyocytes. Cytokine. 2005;30(5):282\u201392.","journal-title":"Cytokine"},{"issue":"2","key":"454_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0008-6363(03)00534-0","volume":"60","author":"DH Freed","year":"2003","unstructured":"Freed DH, Borowiec AM, Angelovska T, Dixon IM. Induction of protein synthesis in cardiac fibroblasts by cardiotrophin-1: integration of multiple signaling pathways. Cardiovasc Res. 2003;60(2):365\u201375.","journal-title":"Cardiovasc Res"},{"issue":"13","key":"454_CR19","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1161\/01.CIR.0000013839.41224.1C","volume":"105","author":"DB Sawyer","year":"2002","unstructured":"Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation. 2002;105(13):1551\u20134.","journal-title":"Circulation"},{"issue":"2","key":"454_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11523-009-0106-0","volume":"4","author":"KL Snider","year":"2009","unstructured":"Snider KL, Maitland ML. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Target Oncol. 2009;4(2):67\u201376.","journal-title":"Target Oncol"},{"issue":"2","key":"454_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa035153","volume":"351","author":"SE Lipshultz","year":"2004","unstructured":"Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, et al. The effect of Dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004;351(2):145\u201353.","journal-title":"N Engl J Med"},{"issue":"8","key":"454_CR22","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/MCA.0b013e32834d3346","volume":"22","author":"CA Geisberg","year":"2011","unstructured":"Geisberg CA, Wang G, Safa RN, Smith HM, Anderson B, Peng XY, et al. Circulating neuregulin-1beta levels vary according to the angiographic severity of coronary artery disease and ischemia. Coron Artery Dis. 2011;22(8):577\u201382.","journal-title":"Coron Artery Dis"},{"issue":"6","key":"454_CR23","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1200\/JCO.2002.20.6.1677","volume":"20","author":"SE Lipshultz","year":"2002","unstructured":"Lipshultz SE, Giantris AL, Lipsitz SR, Kimball Dalton V, Asselin BL, Barr RD, et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91\u2009\u2013\u200901 acute lymphoblastic leukemia protocol. J Clin Oncol. 2002;20(6):1677\u201382.","journal-title":"J Clin Oncol"},{"issue":"4","key":"454_CR24","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S0735-1097(84)80397-6","volume":"4","author":"SD Colan","year":"1984","unstructured":"Colan SD, Borow KM, Neumann A. Left ventricular end-systolic wall stress-velocity of fiber shortening relation: a load-independent index of myocardial contractility. J Am Coll Cardiol. 1984;4(4):715\u201324.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"454_CR25","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJM199103213241205","volume":"324","author":"SE Lipshultz","year":"1991","unstructured":"Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324(12):808\u201315.","journal-title":"N Engl J Med"},{"issue":"2","key":"454_CR26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1152\/japplphysiol.01144.2004","volume":"99","author":"T Sluysmans","year":"2005","unstructured":"Sluysmans T, Colan SD. Theoretical and empirical derivation of cardiovascular allometric relationships in children. J Appl Physiol. 2005;99(2):445\u201357.","journal-title":"J Appl Physiol"},{"issue":"1\u20132","key":"454_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ppedcard.2014.09.012","volume":"36","author":"N Bansal","year":"2014","unstructured":"Bansal N, Franco VI, Lipshultz SE. Anthracycline cardiotoxicity in survivors of childhood cancer: clinical course, protection, and treatment. Prog Pediatr Cardiol. 2014;36(1\u20132):11\u20138.","journal-title":"Prog Pediatr Cardiol"},{"issue":"2","key":"454_CR28","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s00395-013-0334-4","volume":"108","author":"E Piegari","year":"2013","unstructured":"Piegari E, De Angelis A, Cappetta D, Russo R, Esposito G, Costantino S, et al. Doxorubicin induces senescence and impairs function of human cardiac progenitor cells. Basic Res Cardiol. 2013;108(2):334.","journal-title":"Basic Res Cardiol"},{"issue":"15 suppl","key":"454_CR29","doi-asserted-by":"publisher","first-page":"10021","DOI":"10.1200\/jco.2014.32.15_suppl.10021","volume":"32","author":"SE Lipshultz","year":"2014","unstructured":"Lipshultz SE, Scully RE, Stevenson KE, Franco VI, Neuberg DS, Colan SD, et al. Hearts too small for body size after doxorubicin for childhood ALL: grinch syndrome. J Clin Oncol. 2014;32(15 suppl):10021. (abstract).","journal-title":"J Clin Oncol"},{"issue":"5","key":"454_CR30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00395-007-0674-z","volume":"102","author":"P Fischer","year":"2007","unstructured":"Fischer P, Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: the gp130-STAT axis. Basic Res Cardiol. 2007;102(5):393\u2013411.","journal-title":"Basic Res Cardiol"},{"issue":"15","key":"454_CR31","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1161\/01.CIR.101.15.1767","volume":"101","author":"PM Ridker","year":"2000","unstructured":"Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101(15):1767\u201372.","journal-title":"Circulation"},{"issue":"5","key":"454_CR32","first-page":"412","volume":"12","author":"N Khuseyinova","year":"2006","unstructured":"Khuseyinova N, Koenig W. Biomarkers of outcome from cardiovascular disease. Curr Opin Crit Care. 2006;12(5):412\u20139.","journal-title":"Curr Opin Crit Care"},{"issue":"6\u20137","key":"454_CR33","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.ejheart.2007.01.003","volume":"9","author":"T Tsutamoto","year":"2007","unstructured":"Tsutamoto T, Sakai H, Ishikawa C, Fujii M, Tanaka T, Yamamoto T, et al. Direct comparison of transcardiac difference between brain natriuretic peptide (BNP) and N-terminal pro-BNP in patients with chronic heart failure. Eur J Heart Fail. 2007;9(6\u20137):667\u201373.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"454_CR34","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0735-1097(01)01576-5","volume":"38","author":"T Tsutamoto","year":"2001","unstructured":"Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001;38(5):1485\u201390.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"454_CR35","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1161\/HYPERTENSIONAHA.107.098111","volume":"50","author":"B Lopez","year":"2007","unstructured":"Lopez B, Castellano JM, Gonzalez A, Barba J, Diez J. Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension. Hypertension. 2007;50(5):977\u201383.","journal-title":"Hypertension"},{"issue":"2","key":"454_CR36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cardfail.2011.10.015","volume":"18","author":"L Tarantini","year":"2012","unstructured":"Tarantini L, Cioffi G, Gori S, Tuccia F, Boccardi L, Bovelli D, et al. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail. 2012;18(2):113\u20139.","journal-title":"J Card Fail"},{"issue":"6","key":"454_CR37","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1179\/joc.2010.22.6.402","volume":"22","author":"T Chen","year":"2010","unstructured":"Chen T, Zhou G, Zhu Q, Liu X, Ha T, Kelley JL, et al. Overexpression of vascular endothelial growth factor 165 (VEGF165) protects cardiomyocytes against doxorubicin-induced apoptosis. J Chemother. 2010;22(6):402\u20136.","journal-title":"J Chemother"},{"issue":"3","key":"454_CR38","first-page":"257","volume":"22","author":"X Chen","year":"2002","unstructured":"Chen X, Zhang J, Ke Q, Zhang Y, Liu C. Long-term administration of angiotension-converting enzyme inhibitor improves the outcome of chronic heart failure in senile patients. J Huazhong Univ Sci Technolog Med Sci. 2002;22(3):257\u20139.","journal-title":"J Huazhong Univ Sci Technolog Med Sci"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-026-00454-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00454-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00454-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:08:13Z","timestamp":1773659293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40959-026-00454-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["454"],"URL":"https:\/\/doi.org\/10.1186\/s40959-026-00454-6","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review board of each participating institution and all subjects and\/or their parent\/guardian provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}